Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
![](/46/pdcnewsitem/12/10/33/CPHI%20images%20(42).png)
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Biotechnology company Novavax have partnered with the Bill and Melinda Gates Research Institute in a 3-year agreement to provide the adjuvant Matrix-M for use in preclinical vaccine research. Adjuvants are ingredients in vaccines that enhance the immune system’s response, resulting in broader and longer-lasting immunity towards pathogens.
Matrix-M, in particular, enhances the entry of antigen-presenting cells at the injection site, promoting their production at local lymph nodes. The ingredient is a key component in Novavax’s COVID-19 vaccine, and the company has begun investigations into its use for vaccines in other disease areas. The saponin-based Matrix-M has also been utilised in global clinical and preclinical trials for human and animal vaccine development.
The Bill and Melinda Gates Research Institute will be partnering with Novavax to further develop their own commitments to developing biomedical interventions addressing global health needs. “The Bill and Melinda Gates Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need,” stated Emilio Emini, PhD, CEO of the Bill and Melinda Gates Medical Research Institute. “We look forward to working with Novavax’s Matrix-M adjuvant in some of our early-stage vaccine programs.”
Novavax is committed to the discovery and development of vaccines against infectious diseases, as well as their commercialisation. “We are excited to partner with the Bill and Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts,” John Jacobs, President and CEO of Novavax, commented. “Our Matrix-M adjuvant is proven to enhance and broaden the immune system response when included in vaccines and is already a key component of COVID and malaria vaccines on the market today. We look forward to partnering more broadly with a variety of organisations so that our technology can benefit vaccine development across many disease areas.”
Source: Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research [Accessed June 6, 2023] https://ir.novavax.com/2023-06-05-Novavax-Announces-Agreement-with-Bill-Melinda-Gates-Medical-Research-Institute-to-Include-Matrix-M-TM-Adjuvant-as-Potential-Component-in-Vaccine-Research
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance